Description du projet
Introduction de la pharmacogénomique dans la pratique clinique
Les effets indésirables des médicaments tuent des centaines de milliers de patients chaque année rien qu’en Europe. Le développement de la pharmacogénomique (PGX) pour personnaliser les thérapies et améliorer les résultats des traitements revêt donc une grande importance. Le projet PharmGenHUB, financé par l’UE, soutiendra les efforts de plusieurs partenaires universitaires, coordonnés par l’Institut de génétique moléculaire et de génie génétique de l’université de Belgrade en Serbie, en vue de développer les diagnostics, l’éducation, la formation en matière de PGX et de traduire les connaissances sur les PGX en solutions numériques destinées aux applications médicales dans la région des Balkans occidentaux (BO). Le projet utilisera le séquençage de l’ADN à haut débit pour identifier les paires de marqueurs médicament-PGX spécifiques aux BO et pour concevoir des outils électroniques permettant la personnalisation du traitement dans la pratique clinique.
Objectif
Personalized medicine uses pharmacogenomics (PGX) to individualize therapy upon patients’ unique DNA profiles. With ~200,000 deaths/year in Europe due to adverse drug reactions, it has become an imperative to improve treatment. In Western Balkans (WB), individualization of therapy is done sporadically. IMGGE (Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Serbia) is a pioneer in the PGX in WB. PharmGenHUB will strengthen IMGGE’s PGX R&I potential by exchanging knowledge between IMGGE and EU partnering institutions: University of Patras, Greece (UPAT), University of Ljubljana, Slovenia (UL), University of Trieste, Italy (UNITS). Through collaboration and knowledge sharing with 3 EU partners, IMGGE will become WB central place for PGX diagnostics and R&I, education and trainings, and translation of PGX knowledge into clinically applicable digital solutions. IMGGE’s research project, high-throughput DNA sequencing of WB populations, with support of UPAT and UL, will identify WB specific drug-PGX marker pairs and enable design of electronic tool for better decision-making in clinical practice, electronic PGX assistant for WB (ePGA-WB). iPSC model for validation of novel PGX markers relevant for Europe will be introduced at IMGGE with support of UNITS. IMGGE will renew, reinforce and establish new connections through networking with WB institutions. Project will be realized through short-term visits of IMGGE staff to EU partner institutions, staff exchanges, on-site trainings, experimental laboratory work. Outreach activities will include PGX days, WB conference and joint summer schools. To strengthen research management capacities and administrative skills of IMGGE staff, a research management unit will be established with assistance from UPAT. As focal point of PGX translational research, IMGGE will impact on WB health-care cost benefits and facilitate WB integration to EU-PGX research area through R&I activities and digitalization.
Programme(s)
Régime de financement
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinateur
11010 Beograd
Serbie